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Exosomes are nanosized vesicles released from every cell in the body including those in the respiratory tract and lungs. They
are found in most body fluids and contain a number of different biomolecules including proteins, lipids, and both mRNA and
noncoding RNAs. Since they can release their contents, particularly miRNAs, to both neighboring and distal cells, they are
considered important in cell-cell communication. Recent evidence has shown their possible importance in the pathogenesis of
several pulmonary diseases. The differential expression of exosomes and of exosomal miRNAs in disease has driven their promise
as biomarkers of disease enabling noninvasive clinical diagnosis in addition to their use as therapeutic tools. In this review, we
summarize recent advances in this area as applicable to pulmonary diseases.
1. Introduction
Biological markers (biomarkers) were initially described by
Hulka as “cellular, biochemical or molecular alterations that
are measurable in biological media such as human tissues,
cells or fluids” [1]. Today this definition has been broadened
and includes biological features that can be measured and
evaluated to reflect a particular physiological or biological
state and includes specific analytes through to physiological
measures such as blood pressure. Biomarkers act as indicators
to enable the evaluation of a normal or pathogenic condition
or the response to therapy [2].
In pulmonary diseases, biomarkers are powerful tools
in understanding the spectrum of pathological conditions
affecting the lung microenvironment and function as well as
predicting drug responses.The expressions of many proteins,
lipids, and genomic biomarkers have been investigated due
to their possible central roles in the biology of human lung
diseases [3]. MicroRNAs (miRNAs) have been studied in
many diseases due to their utility in disease diagnostics for
monitoring therapy and to predict the probability of disease
recurrence [4]. Recent studies have shown that miRNAs have
central roles in multiple aspects of lung inflammation and
disease pathogenesis [3–9].
Exosomes are extracellular membrane vesicles involved
in cell-cell communication by shuttling various molecules
including miRNAs from donor to recipient cells [10]. Exoso-
mal miRNAs delivered to target cells can significantly affect
biological pathways within target/recipient cells resulting in
altered cellular function and the development of a pathologi-
cal state [11]. The packaging of miRNAs within the exosomal
lipid bilayers protects them from enzymic degradation by
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Figure 1: Exosomes properties and function exosomes are secreted
membrane vesicles released into the extracellular space and transfer
proteins, lipids, nucleic acids, and other hosts’ cellular content.
The fusion of the exosome membrane with the target cell plasma
membrane results in the release of exosome content into the target
cell cytoplasm.
body fluids resulting in a relatively long and stable duration of
expression [11, 12]. In this review, we aim to summarize recent
advances regarding the status of exosomes and exosomal
miRNAs as potential biomarkers in lung diseases.
2. Exosomes Properties and Function
Exosomes are small, 30–120 nm in diameter, cell-derived
vesicles which are secreted from most cell types (Figure 1).
They are ubiquitous in body fluids including urine, plasma,
breast milk, bronchoalveolar lavage (BAL) fluid, saliva, sem-
inal fluid, amniotic liquid, ascites, synovial fluid, breast milk,
and cerebrospinal fluid (CSF) [13, 14]. The initial discovery
of exosomes in the mid-1980s referred to small vesicles that
bud from reticulocytes during their maturation to eliminate
some membrane bound proteins [15]. These exosomes were
originally thought to function as the cell’s “garbage bin”
and so received little attention but further studies indicated
that these small exocytosed vesicles were not specific to
reticulocytes and were released from most mammalian cells
[14]. Later, exosomes were shown to have immune regulatory
effects, with the demonstration that B-cell-derived exosomes
could stimulate T cells [16, 17]. Additional studies highlighted
the role of exosomes in tumorigenicity, immune modulatory
processes, neurodegenerative disease, and the transfer of
infectious agents [18–20]. The turning point in exosome
research was in 2007 with the finding that exosomes released
from mast cells contain over 1200 mRNAs which could be
transferred to other cells and be translated into proteins
[21, 22].
According to ExoCarta, a database of exosomal proteins,
RNA, and lipids [23], exosomes have a complex composition
whose molecular content is dependent upon their cell of
origin. 4,563 proteins, 194 lipids, 1,639 mRNAs, and 764
miRNAs have been recognized in exosomes from different
species with membrane transport proteins and fusion pro-
teins being most frequently detected [23]. Some exosomal
proteins are universal including tetraspanins, CD63, CD81,
CD9, and heat shock protein (Hsp70) and these are com-
monly used as exosomal markers [24]. Exosomes are rich in
lipids such as cholesterol, phospholipids, phosphatidylserine,
and prostaglandins but lack nuclear, mitochondrial, and
ribosomal proteins but, importantly in the context of this
review, contain both mRNAs and miRNAs [23] (Figure 2).
Circulating exosomes are highly stable in biological fluids
[11] and can, therefore, provide a great deal of information
about the physiological and pathological status of the origi-
nating cell via accessing their molecular contents [15, 25, 26].
As a result, comprehensive analysis of exosomal miRNA is
defining novel therapeutic and diagnostic targets for a variety
of pulmonary diseases [26].
3. The Potential of Exosomes in Diagnostics
Exosomes can pass through the blood-brain barrier andmove
to distant tissues, where they fuse with the cell membranes
of target cells to transfer their contents [24]. Due to their
donor cell characteristics and the ability to provide cell-cell
communication, exosomes are increasingly viewed as disease
biomarkers which require minimally invasive procedures to
interrogate the biology of difficult-to-access cells and organs
[27].
The presence of pathogen-derived antigens in the exo-
somes was firstly suggested by Beatty et al. in 2000 [28].
Exosomes released by infected cells carry a variety of
pathogen-derived molecules which can act as biomarkers for
specific infectious agents [16, 29] exemplifying the potential
role of exosomes in the diagnosis of infectious diseases. In
allergic mouse models of asthma, exosomes obtained from
bronchoalveolar lavage (BAL) of allergic mice protect na¨ıve
mice against airway inflammation [30].
The number and contents of exosomes in body fluids
may change significantly with disease. For example, there are
increased numbers of BAL exosomes in sarcoidosis patients
compared with healthy volunteers [31]. BAL exosomes from
sarcoidosis patients induce the production of inflammatory
cytokines by PBMCs and promote the release of CXCL-
8 by airway epithelial cells through delivery of pathogen-
associated proinflammatory mediators [31]. In addition,
increased numbers of circulating exosomes are associated
with disease progression in cancer [30, 32]. The exosomal
content may also provide valuable information about disease
status [33]. Exosomes from macrophages from patients with
active M. tuberculosis infection contain a highly antigenic
mycobacterium protein compared with the lack of antigenic
protein observed in patients with latent infection [34, 35].
In addition, exosomes derived from Mycobacterium avium
infected macrophages also contain pathogenic proinflamma-
tory glycopeptidolipids [16].
Different exosomal content signatures are also found
in bladder and gastric cancer [36, 37]. 8 proteins are dif-
ferentially expressed in urinary exosomes of patients with
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Figure 2: Structure and contents of exosomes: exosomes contain a plasma membrane-derived phospholipid bilayer membrane. Exosomal
contents based on the cell type of origin include mRNA, miRNA, and DNA and proteins such as annexins, tetraspanins, MHC molecules,
cytoskeletal proteins, enzymes, and signal transduction proteins.
bladder cancer and these are indicated as potential disease
biomarkers [38]. Enhanced expression of oncogenic HER-
2/neu and MAGE-1 mRNA is found in exosomes isolated
from various body fluids of patients with gastric cancer [38].
Overall, the analysis of exosomal content may be useful
for the early detection of various diseases including cancers
and infectious diseases and a sensitive diagnostic test for
prostate cancer based on analysis of exosomal proteins was
recently launched (http://www.carislifesciences.com/) [39].
4. The Potential of Exosomes in Therapeutics
Exosomes are important regulators ofmany functions includ-
ing tissue homeostasis, immune stimulatory or immuno-
suppressive functions, and tumorigenicity [30]. In addition,
exosomes released from antigen presenting cells (APCs)
contain MHC-I, MHC-II, and CD86 and can act in a similar
manner to APCs [13, 17, 40, 41] and dendritic cell- (DC-)
derived exosomes are as effective as DCs in inducing some
immune responses [42]. For example, exosomes derived
from DCs pulsed with tumor antigens induce a very strong
immune response resulting in the rejection of established
tumors in mice [30]. This phenomenon probably occurs due
to the high density of tumor antigens and the presence of
HSPs in exosomes which act like an adjuvant. In addition,
exosomes containing HSP70 have recently been shown to be
proinflammatory by activating natural killer cells (NKs) and
macrophages [43].
These properties of exosomes have been utilized in phase
I [44, 45] and phase II clinical trials for inoperable non-
small cell lung cancer. NK cell-derived exosomes, containing
perforin and granzyme B, have also shown antitumor activ-
ities in vitro or in vivo [43, 46]. Further, it was observed
that exosomes derived from tumor cells (tumor exosomes
or TEX) can induce an antitumor immune response [30,
47]. TEX suppress NK cell function via modulation of
NKG2D receptor expression [43, 48]. It was later shown that
immunization of mice with TEX or with DCs pulsed with
TEX led to a significant reduction in tumor growth and an
increased survival [49, 50] and the use of exosomes in cancer
immunotherapy is promising.
However, exosomes have also been reported to be
involved in promoting cancer growth. For example, exosome-
mediated transportation of the oncoproteins K-RAS and
MET and their uptake by other cells promote an optimal local
tumor microenvironment [51]. TEX may contain different
levels of oncogenic miRNAs which may affect acceptor cell
function via posttranscriptional modulation [25]. Metastasis
requires a specific microenvironment termed “premetastatic
niche,” which allows the colonization and growth of tumor
cells in a secondary organ at unique distant sites. The forma-
tion of premetastatic niches has been attributed to exosomes
directing the disseminated tumor cells to future metastatic
sites [52, 53]. Exosome-mediated metastasis occurs in a non-
randommanner and is directed to the future site ofmetastasis
according to the TEX integrin expression profile [54].
The potential role of exosomes in the treatment of allergy
and infectious diseases has also been investigated. Exosomes
released from DCs laden with pathogen-derived antigens
can protect against infection [30]. In contrast, exosomes can
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also contain exogenous viral RNAs and be involved in the
spreading of infection [55]. On the other hand, due to their
biological properties, exosomes have also been proposed as
possible delivery vectors for therapeutic purposes [56] and
vaccine delivery vehicles [57, 58]. Indeed, the first two phase
I trials in human cancer have been published using exosomes
from monocyte-derived DCs loaded with tumor antigens
[44, 59–61].
5. Putative Roles of Exosomes in Lung
Microenvironment and Pathogenesis
The lung is a unique organ considering the broad range
of cells that are found within the parenchyma and air-
way structures. Cell-cell communication is essential for
the optimal functioning of the lung and so exosomes are
expected to be important players in lung biology and function
[12]. Exosomes are released by a wide range of cell types
present within the lung including endothelial cells, stem
cells, epithelial cells, alveolar macrophage, and tumor cells,
although epithelial cells are reported to be the main source
of lung-derived exosomes [62]. Exosomes released by airway
epithelial cells containmucins and alpha 2,6-linked sialic acid
which have a neutralizing effect on human influenza virus
infection [12]. Membrane-tethered mucins within epithelial
cell-derived exosomes affect the structural properties, con-
formation, and surface charge of exosomes. The properties
of exosomes contribute to mucociliary defense by the lung’s
innate immune system [63, 64].
Exosomes control inflammatory signaling within the
airway through intercellular communication [4] as elegantly
demonstrated by the transfer of suppressor of cytokine
signaling (SOCS)1 from macrophage-derived exosomes to
alveolar epithelial cells. This attenuates the activation of
signal transducer and activator of transcription (STAT) both
in vitro and in vivo [62]. Exosomes derived from alveolar
macrophages also regulate airway inflammation through the
transfer of miR-223 to various respiratory cells resulting in
cellular homeostasis and differentiation [65].
Exosomes may also act as a part of the stress response
in the airway. In sarcoidosis, exosomes cause the initiation
and progression of inflammatory responses by enhancing the
induction of IL-13, INF-gamma, and CXCL-8 production in
the lung microenvironment [31]. Furthermore, the secretion
of exosomes and the composition of the secreted exosomes
can be altered following infection. For example, it was shown
that alveolar macrophage-derived exosomes are enriched for
HSP-70 after infection withMycobacterium [66].
6. Biomarker Discovery Using Exosomal
miRNAs in Lung Diseases
Based on the available evidence, various types of cell-derived
exosomesmay regulate airway homeostasis and contribute to
the pathogenesis of various lung diseases [62]. One of the
most attractive aspects of exosome research in pulmonary
disease is in the context of novel diagnostic and/or prognostic
biomarkers for the early detection and improved treatment of
patients particularly with respect to lung cancer. The miRNA
profiles of TEX are similar to the corresponding tumor
miRNA signatures [67] and are also related to their donor cell
inflammatory status [25, 68, 69]. This suggests that exosomal
miRNAs may act as potential noninvasive biomarkers for
the diagnosis of lung cancer and other pulmonary diseases
[12, 70].
The crucial roles of exosomes in the initiation and devel-
opment of inflammatory airway diseases such as asthma,
COPD, sarcoidosis, and tuberculosis and their possible role
as biomarkers are reviewed further in the following sec-
tion.
7. Tuberculosis
Eradication of tuberculosis (TB) has been hampered partly
by the ability of Mycobacterium tuberculosis (MTB) to
remain dormant in the human body for years without
causing disease, a state referred to as latent tuberculosis [71].
Comprehensive proteomic based analysis has determined
the protein content of exosomes derived from macrophages
infected with either live or dead M. tuberculosis in vitro
[72]. This revealed the dominant presence of host pro-
teins along with 41 mycobacterial proteins within the
secreted exosomes. Further analysis indicated the presence
of highly immunogenic Mycobacterium proteins including
antigen SAT-6 (Rv3875), Ag85 complex (Rv3804c, Rv1886c,
and Rv0129c), MPT64 (1980c), and MPT63 (1926c) [7,
57, 58]. Subsequent studies identified twenty mycobacte-
rial proteins in exosomes isolated from the serum of TB
patients including the antigens 85b, BfrB, GlcB, and Mpt64
[34].
In addition, it is possible to distinguish pulmonary and
extrapulmonary TB based on exosomal markers in serum
such asMPT64 [34] and to recognize active and latent disease
[34]. The ability to detect latent from active infection is
particularly important within an endemic population and
could improve monitoring of at risk persons and prevent
the transmission of infection. Importantly, some of the M.
tuberculosis products found in exosomes were identical in
cell culture, animal models, and human clinical specimens
[8, 57].
Exosomes released fromCFP-treatedmacrophages (CFP:
M. tuberculosis culture filtrate proteins) are able to activate
both innate and acquired immune responses. In these exo-
somes, 29 M. tuberculosis proteins were detected with the
majority overlapping with those present in the exosomes
isolated from M. tuberculosis-infected macrophages. These
exosomes could stimulate macrophages, DCs, and na¨ıve T
cells in vivo.This indicates that exosomeswithM. tuberculosis
antigen cargo may be a suitable vehicle for the development
of tuberculosis CFP-based vaccines [7].
Exosomes are also reported to act as carriers of pathogen-
associatedmolecular patterns (PAMPs) and to affect recipient
cells by either silencing or promoting the immune responses
[70]. M. tuberculosis (Mtb) can induce partial resistance to
INF-gamma stimulation in infected macrophages via PAMPs
such as the 19 kDa lipoprotein and mycolyl-arabinogalactan-
peptidoglycan complex (mAGP complex) binding to Toll-like
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receptor (TLR)2 on macrophages [73]. This effect is mim-
icked by exosomes released fromMtb-infected macrophages
[20].
Interestingly, it has been shown that genome-wide Mtb
infection induced miRNA expression profile in primary
human macrophages [74]. In this way infection of human
macrophages with virulent Mtb H37Rv and avirulent M.
bovis BCG results in a pattern of miRNA expression mostly
overlapping between the two live mycobacteria considered,
while a substantially different pattern emerged from infection
with killed Mtb bacilli suggesting an active influence of live
intracellular bacteria on cell target miRNA metabolism [74].
Overall, the amount of exosomal miRNAs from M.
tuberculosis-infected macrophages is significantly lower in
comparison with those from uninfected cells. Additionally,
more than 100mRNAswere unique to the exosomes from the
infected cells and these may be involved in the regulation of
immune responses in recipient cells [75]. This data supports
the functional and diagnostic potential of exosomal mRNAs
and miRNAs in tuberculosis.
8. COPD
The persistence of inflammation is characteristic of COPD
[76] and it is plausible that exosomes play a key role in COPD
by regulating this inflammation [77]. COPD is induced by
chronic exposure of the airway to irritants including cigarette
smoke which leads to epithelial cell injury, destruction of
pulmonary capillary vasculature, acceleration of epithelial
cell senescence, and airway remodeling which results in
the loss of lung function [78, 79]. Endothelial cell injury
within the lung parenchyma is an important factor in emphy-
sema [80] and a group of endothelial-derived microparticles
(EMPs) are increased in patients with stable COPD and dur-
ing exacerbation. These EMPs contain vascular endothelial-
cadherin, platelet endothelial cell adhesion molecule, and
E-selectin. Importantly, the level of EMPs in stable COPD
significantly correlated with lung destruction and airflow
limitation [81]. These results indicate the close relationship
between endothelial lung injury and EMP function in the
pathophysiology of COPD.
Airway epithelial cell injury is also important in COPD
pathogenesis. Injured lung epithelial cells are a source of
inflammatory mediators such as TNF-𝛼, IL-1𝛽, GM-CSF,
TGF𝛽, and CXCL-8 which may act in both autocrine and
paracrine manners. TGF𝛽 induces the remodeling of airway
cells by regulation and promoting ofmyofibroblast differenti-
ation which is the main cause of fibrosis development during
airway remodeling. The level of TGF𝛽 in the small airway
epithelium of COPD patients is correlated with the severity
of airway obstruction [8].
The paracrine activity of these mediators is mediated, at
least in part, by exosomes [82]. This mechanism has been
suggested as causing epithelial cell death and lung tissue loss
upon chronic exposure of cigarette smoke (CS). Prolonged
exposure to CS induced the release of the CCN1-enriched
exosomes from lung epithelial cells. CCN1 plays an important
role in tissue remodeling and repair process as an extra-
cellular matrix protein [83] and enhances CXCL-8 release
from cells via theWnt signaling pathway [84]. Hence, CCN1-
enriched exosomes could lead to the paracrine induction of
CXCL-8 secretion in the lung mesenchyme or parenchyma
and the subsequent recruitment of inflammatory cells such
as neutrophils which will result in lung tissue fibrosis [62, 83,
85]. CS can increase the numbers of circulating lung epithelial
cell-derived exosomes [86] and the degree of lung endothelial
injury in COPD may be predicted by circulating exosomes
[2]. This suggests that, in addition to being important drivers
of COPD pathophysiology, exosomes may also serve as
biomarkers of COPD progress and treatment [81].
Alpha 1 anti-trypsin (AAT1) deficiency is observed in
∼1.5% of COPD patients [81, 86]. AAT1 is a glycoprotein
serine protease which protects the lung from inflammatory
insults [87]. Lung endothelial cells transport AAT1 to the
alveolar epithelium and air spaces packaged in exosomes
which are rapidly internalized by epithelial cells. Efficient
trafficking of AAT1-containing exosomes across an uninjured
lung endothelial barrier may be involved in the protective
effect against CS [88].
Epithelial mesenchymal transition (EMT) is another
important component of small airway remodeling and fibro-
sis in COPD [89, 90]. Increased urokinase plasminogen
activator receptor (uPAR) expression in the small airway
epithelium is a sign of an active EMT process occurring in
patients with COPD [87]. EMT can also be linkedwith angio-
genesis (termed EMT-type-3) in the large airway resulting
in the formation of a procancer stromal niche [91–94]. Up
to 70% of lung cancers occur in COPD patients with mild-
to-moderate disease [95]. Based on the ability of exosomes
to transfer bioactive molecules between cells and to affect
recipient cell function, a role for exosomes in EMT has
been proposed [91].Disruption of the epithelialmesenchymal
trophic unit (EMTU) is observed in COPD [94]. The EMTU
consists of one epithelial cell layer, the basement membrane
zone (BMZ), and mesenchymal cells including fibroblasts
[96]. EMTUfibroblasts are involved in repair and remodeling
processes associated with the increased small airway thick-
ness in COPD [97] possibly as a result of extensive transfer of
paracrine mediators by exosomes [62].
The plasma level of circulating muscle-specific miRNAs
(myomirs) is different between COPD and non-COPD sub-
jects and there is an association between the reduction of
some myomirs and skeletal muscle weakness and changes in
quadriceps fiber composition [98]. It is suggested that the
plasma level of exosomal miRNA can reflect changes within
the skeletal muscle and so can act as a biomarker of skeletal
muscle dysfunction [98]. A recent abstract has reported on
the level of exosomal miRNAs in BAL fluid and serum of
mild-to-moderate COPD patients compared with healthy
controls [99]. One miRNA was significantly upregulated in
serum and 4 miRNAs were significantly downregulated in
BAL fluid of COPD patients. In silico and in vitro analysis
identified ribosomal s6 kinase (S6K) as the main target of
these miRNAs. S6K is part of the mTORC1 signaling pathway
which is a key regulator of skeletal muscle wasting. This
highlights the potential of exosomal miRNAs as noninvasive
diagnostic biomarkers [99].
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9. Sarcoidosis
Pulmonary sarcoidosis is a systematic, inflammatory disease
with unknown etiology. It is characterized by the formation
of noncaseating granulomas predominantly in lung and
the presence of interferon- (IFN-) producing T cells which
leads to inflammation and tissue damage in multiple organs,
especially the lung [31, 100]. In the context of the molecular
pathogenicity of sarcoidosis, the expression profile of intra-
cellular miRNAs has been reported in a number of studies
[101–103] but there is limited information regarding exo-
somes and exosomal miRNAs in sarcoidosis. The first study
demonstrated that increased numbers of exosomes could be
isolated from the BAL fluid of sarcoidosis patients compared
to healthy individuals. The BAL exosomes from sarcoidosis
patients induced higher levels of IFN𝛾 and interleukin-13
production by PBMCs and CXCL-8 production by epithelial
cells in comparison to that induced by exosomes fromhealthy
individuals [31].
In a recent abstract, the profile of exosomal miRNA
in BAL fluid and serum of sarcoidosis patients has been
investigated. In this study, miR-21, miR-26a, and miR-146a
miRNAs were detected in BAL exosomes by RT-PCR with
no expression of miR-15a, miR-129, miR-133a, miR-133b,
miR-134, miR-195, miR-452, and miR-589 observed [104].
This study indicated the potential roles of exosomes in the
initiation and progression of inflammation in sarcoidosis but
more work is needed to fulfill the promise that exosomes
may be a new potential target for the clinical treatment of
sarcoidosis.
10. Asthma
Asthma is a heterogeneous chronic inflammatory airways
disease, characterized by reversible airway narrowing and/or
airway hyperresponsiveness in response to nonspecific stim-
uli such as exercise, allergens, infections, and air pollutants
[105]. The main features of asthma are due to the patho-
physiological effects of proinflammatory cytokines such as
IL-4, IL-5, and IL-13 released by activated CD4+ T cells
in response to environmental stimuli [105]. Expression of
these mediators results in increased numbers or activation
status of mast cells, Th2 cells, and eosinophils along with
airway remodeling, reversible airway hyperresponsiveness,
and airway obstruction [106].
Exosomes released from the key cells involved in asthma
such as mast cells, eosinophils, DCs, T cells, and bronchial
epithelial cells can induce priming and activation of other
asthma-associated cells. For example, DC-derived exosomes
activate allergen-specificTh2 cells [107].These exosomes con-
tain costimulatory molecules and major histocompatibility
complex classes I and II on their surfaces which help them
to induce the antigen-specific activation of T cells [108].
In addition, eosinophil-derived exosomes are increased in
asthmatic patients and can modulate features of asthma in
vitro after transfer to recipient cells [109].
Exosomes may also have beneficial effects. Thus, despite
exosomes being able to enhance allergic responses, tolerizing
exosomes that block allergic responses and prevent the
initiation and development of an allergic response have
also been reported [110]. Intranasal transfer of BAL fluid-
derived exosomes from a tolerized mouse prevents allergic
sensitization. It has been suggested that exosomes-based
vaccines could be a therapeutic option for asthma and other
allergic diseases [110].
The exosome profiles of BAL fluid of asthmatic patients
were compared to those from healthy individuals. The BAL-
derived exosomes from patients with asthma promoted
production of CXCL-8 and leukotriene C4 by bronchial
epithelial cells. These BAL-derived exosomes contain the
epithelial marker mucin 1 on their surface suggesting that
they originated from bronchial epithelial cells [111].
IL-13 can drive airway epithelial cells to produce exo-
somes which, in turn, promoted the proliferation of undiffer-
entiated lung macrophages [112]. The profile of BAL-derived
exosomal miRNAs in asthma shows differential expression
of 24 miRNAs compared to those from healthy individuals.
A number of these altered miRNAs are involved in IL-
13-mediated events and a significant correlation was seen
between the expression of these miRNAs and pulmonary
function [113]. Further studies on exosomes and exosomal
miRNAs in asthma will provide additional insight into cell-
cell communication in asthma and may also help define the
mechanism(s) underlying the various subgroups of patients
with this disease.
11. Other Respiratory Diseases
In addition to the above-mentioned respiratory diseases, the
role of exosomes in some other lung disorders has also been
investigated. Hypoxia causes an elevation of proinflamma-
tory mediator expression and the presence of alternatively
activated macrophages during the progression to hypoxic
pulmonary hypertension [114]. Hypoxia evokes the release of
a large number of lung epithelial cell-derived exosomes fol-
lowing endoplasmic reticulum (ER) stress. These exosomes
are enriched for caspase-3 and mediate the activation of
alveolar macrophages and the initiation and propagation of
the inflammatory responses resulting in lung injury. These
results highlight the role of exosomes in lung epithelial cell-
macrophage communication in the development of tissue
injury [115].
There are few therapeutic options for Idiopathic Pul-
monary Fibrosis (IPF) and it has a dismal median survival
of 2-3 years [116]. It has recently been reported that exo-
somal miRNAs in IPF patients contain decreased levels of
antifibrotic miRNAs such as miR-141 and increased levels of
fibrogenic miRNAs such as miR-7 compared with control
subjects. There was a good correlation between the degree
of miR-7 upregulation and the burden of disease and also
between miR-125b upregulation and milder disease. These
findings demonstrated the role of exosomal miRNAs as the
biomarkers to gain an insight into the pathogenesis of IPF
[117].
Cystic fibrosis (CF) is a genetic lung disorder, charac-
terized by a deficiency in chloride channel activity, the CF
transmembrane conductance regulator (CFTR), resulting in
the massive neutrophil granulocyte influx in the airways and
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mucostasis [118]. Early evidence suggested that bronchial
epithelial cells from CF patients demonstrate enhanced
release of exosomes [119]. These findings provided an oppor-
tunity to use biofluid exosomes as a rich and noninvasive
source of diagnosis biomarkers in CF patients.
The enzyme prolyl endopeptidase (PE) is essential for
the production of the neutrophil chemoattractant tripeptide
Pro-Gly-Pro (PGP) from collagen and plays a role in airway
remodelling and inflammation [120]. PE is released from
airway epithelial cells via exosomes and this release can
be enhanced by the bacterial mimic LPS acting through
TLR4. Sputum samples fromCF patients who have persistent
bacterial infection demonstrate the presence of exosomes
with increased PE levels which may be important for the
hyperinflammatory state observed in these patients [120]. In
gut biology, basolateral release of exosomes from epithelial
cells is linked to antigen presentation,whereas luminal release
of exosomes occurs in response to TLR4 activation [121].
Analysis of this differential release of exosomes should be
undertaken in CF cells.
Evidence suggests that airway epithelial cells release
vesicles with distinct physical properties and sizes dependent
upon their origin and that this may be particularly important
in disease states [122]. For example, the type and amount of
mucin on the exosomes surface define their size and charge
and this will alter in CF patients which are characterized by
excessive mucus production. In a recent abstract, the same
group reported that there were changes in the exosomes
miRNA and protein cargo that reflected the cellular changes
occurring after an inflammatory challenge; this study shows
that exosomes can change the airway microenvironment to a
hyperinflammatory state in lung CF [123].
Restoration of CFTR function is a major goal of CF
research and recent evidence suggests that utilization of
exosomes may be of benefit in the treatment of this disease
[118]. Exosomes derived from CFTR-positive Calu-3 cells
or from A549 cells transduced with an adenoviral vector
overexpressing a GFP-tagged CFTR (GFP-CFTR) were able
to deliver the GFP-CFTR glycoprotein and mRNA (GFP-
CFTR) to CFTR-deficient nasal epithelial cells and restore
CFTR function in a dose-dependent manner [118].
Overall, the above studies emphasize the key roles of
exosomes in cell-to-cell communication within the lung
microenvironment and also in pathogenicity. Not only are
exosomes important as diagnostic biomarkers but also they
offer new potential avenues in the lung diseases treatment. In
the next section, we review the therapeutic roles of exosomes
in respiratory disorders.
12. Exosomes and Therapeutic
Roles in Lung Diseases: Clinical Trials
and Future Perspectives
Exosomes are involved in intercellular communication and
the maintenance of homeostatic functions in the lung
microenvironment. Lung exosomes originate from a broad
range of respiratory cell types including structural and
immune cells. These exosomes appear to be expressed in
different numbers dependent upon disease status and have
distinct disease-specific constituents. Based on the present
evidence, exosomesmay provide novel diagnostic biomarkers
for a broad range of pulmonary diseases andmay also be used
for therapeutic interventions.
Exosomes derived from mesenchymal stem cells (MSC)
have recently been proposed as having the potential for tissue
repair, wound healing, and lung tissue regeneration [119].
TheseMSC-derived exosomes have special properties includ-
ing antiapoptotic and anti-inflammatory actions [124] and
MSC-based therapy for the treatment of acute respiratory dis-
tress syndrome (ARDS) is currently in phase 1 clinical trials
[125].MSC-derived exosomes are beneficial in animalmodels
of ARDS, where they induce the expression of keratinocyte
growth factor (KGF) in the injured alveolus which restores
lung protein permeability and reduces lung inflammation in
the mouse lung [126]. Immunotherapy using tumor antigen-
loaded DC-derived exosomes (dexosomes) is in phase I
clinical trials for NSCLC [127]. This trial demonstrated that
dexosome therapy was feasible and safe and caused the
induction of both innate and adaptive immune responses in
these patients. Further studies are required to examine the
effect on disease stability and on long-term survival.
13. Conclusion
Exosomes mediate cell-cell communication and have several
advantages for the delivery of information to target cells.
Exosomes have been identified in body fluids where they
are stable and can transfer information/mediators between
organs irrespective of distance. Exosomes are heterogeneous
in size and content and these alter with disease status making
them potentially useful as diagnostic biomarkers for disease
or drug efficacy. Exosomes can also deliver specific mRNAs,
miRNAs, and proteins directly to recipient cells and alter their
function, which suggests that they may be an effective tool to
target therapy to specific cells and organs.
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